Evidence map›Paper›PMID 32174789›Full record

ArticleInternational journal of biological sciences2020

Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways.

Xinxing Lu, Feiya Yang, Dexi Chen, Qinxin Zhao, Dong Chen, Hao Ping, Nianzeng Xing

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 1 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 1 synthesis or guideline pooled it, 191 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. 3-acetyl-11-keto-Materials today. Bio · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Xinxing LuDepartment of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, P.R. China.
Feiya YangDepartment of Urology, National Cancer Center/Chinese Academy of Medical Sciences Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China.
Dexi ChenBeijing You'an Hospital, Capital Medical University, Beijing, P.R. China.
Qinxin ZhaoDepartment of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, P.R. China.
Dong ChenDepartment of Urology, National Cancer Center/Chinese Academy of Medical Sciences Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China.
Hao PingDepartment of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Nianzeng XingDepartment of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, P.R. China.
Capital Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNBeijing Chao-Yang Hospital · CNBeijing YouAn Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Docetaxel is the first-line chemotherapy agent for metastatic prostate cancer. However, the emergence of resistance diminishes its efficacy and limits the survival benefit. Quercetin is a dietary flavonoid which has been shown to have multiple anti-cancer effects. Also, quercetin has been reported to reverse chemo-resistance in many other cancers. This study was to determine whether quercetin could reverse docetaxel resistance in prostate cancer cells and xenograft models, thereby exploring the underlying mechanism. Depending on the docetaxel-resistant cells (LNCaP/R, PC-3/R) which were established from docetaxel-sensitive cells (LNCaP, PC-3), it was demonstrated that quercetin could reverse docetaxel resistance in prostate cancer on proliferation, colony formation, migration, invasion and apoptosis. Although single docetaxel application had little effect on docetaxel-resistant cells, combining docetaxel with quercetin was significantly effective. Combination therapy could maximally inhibited PI3K/Akt pathway and promoted apoptosis. As shown by

Indexed as

AnimalsBlotting, WesternCell Line, TumorCell MovementCell ProliferationDocetaxelFlow CytometryHumansImmunohistochemistryMaleMice, Inbred BALB CMice, NudePhosphatidylinositol 3-KinasesProstatic NeoplasmsProto-Oncogene Proteins c-aktQuercetinDocetaxelPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktQuercetinReceptors, AndrogenAktandrogendocetaxelEMTP-gpPI3Kprostate cancerquercetinresistancestem cell

Identifiers

PMID32174789
PMCPMC7053318
OpenAlexW3005755617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.